-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibrx schedules Sept. 8 webcast to release Phase 2 INBRX-106 first-line HNSCC study endpoint results

PUBT·09/04/2026 20:00:22
Listen to the news
Inhibrx schedules Sept. 8 webcast to release Phase 2 INBRX-106 first-line HNSCC study endpoint results
  • Inhibrx scheduled a Sept. 8 webcast to present primary endpoint results from the Phase 2 portion of its HexAgon HNSCC study.
  • Results have not yet been presented.
  • Trial compares INBRX-106 with pembrolizumab versus pembrolizumab alone in first-line PD-L1 positive metastatic or recurrent head and neck cancer.
  • Update could reset expectations for INBRX-106’s clinical profile, influencing pipeline prioritization and partnering interest.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609041600PR_NEWS_USPR_____LA40703) on September 04, 2026, and is solely responsible for the information contained therein.